千红制药(002550) - 2024 Q4 - 年度业绩预告

Financial Performance - The net profit attributable to shareholders is expected to be between 32,000 and 38,000 million CNY, representing a year-on-year increase of 75.96% to 108.95% compared to 18,186.07 million CNY last year[3] - The net profit after deducting non-recurring gains and losses is projected to be between 25,000 and 30,000 million CNY, reflecting a growth of 74.24% to 109.09% from 14,348.21 million CNY in the previous year[3] - Basic earnings per share are anticipated to be between 0.25 and 0.30 CNY, up from 0.14 CNY in the same period last year[3] Sales and Profitability - The company has achieved significant profit growth despite a decline in sales revenue due to falling drug prices, with major product sales volume continuing to increase and gross margin improving compared to the previous year[4] Non-recurring Items - Non-recurring gains and losses for the reporting period are estimated at approximately 85 million CNY, primarily due to a settlement agreement with Jianyuan Trust, resulting in a payment of 85 million CNY[5] Cautionary Note - The company emphasizes that the earnings forecast is based on preliminary calculations and has not been audited by an accounting firm, urging investors to exercise caution[6]